Research location

Clyde

Ohio, United States

Published trials30

Site observations30

Linked trials published30

Page1 / 1

Research activity in Clyde

Ohio, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 30 trials and 30 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Clyde

30 linked trials · page 1 of 1

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate CancerNCT01251861 · 2011-03-17 · 1 site observation

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerNCT01272037 · 2011-02-28 · 1 site observation

ACTIVE_NOT_RECRUITING

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerNCT01275677 · 2011-02-08 · 1 site observation

Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast CancerNCT01086605 · 2010-05-01 · 1 site observation

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung CancerNCT00986674 · 2009-09-01 · 1 site observation

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by SurgeryNCT00861705 · 2009-07-21 · 1 site observation

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive StageNCT00887159 · 2009-07-16 · 1 site observation

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung CancerNCT00946712 · 2009-07-15 · 1 site observation

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract CancerNCT00942331 · 2009-07-15 · 1 site observation

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast CancerNCT00881361 · 2009-07-01 · 1 site observation

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast CancerNCT00820872 · 2009-02-01 · 1 site observation

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT00798603 · 2008-12-01 · 1 site observation

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast CancerNCT00785291 · 2008-10-13 · 1 site observation

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung CancerNCT00738881 · 2008-10-01 · 1 site observation

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast CancerNCT00684983 · 2008-07-30 · 1 site observation

Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination ChemotherapyNCT00693992 · 2008-06-15 · 1 site observation

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEUNCT00520975 · 2007-11-01 · 1 site observation

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By SurgeryNCT00324805 · 2007-07-19 · 1 site observation

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DNCT00490139 · 2007-05-16 · 1 site observation

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By SurgeryNCT00408408 · 2006-11-01 · 1 site observation

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyNCT00337077 · 2006-11-01 · 1 site observation

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast CancerNCT00382070 · 2006-08-01 · 1 site observation

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone TherapyNCT00134056 · 2006-08-01 · 1 site observation

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)NCT00310180 · 2006-04-07 · 1 site observation

ACTIVE_NOT_RECRUITING

Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or AcquaintanceNCT00309933 · 2006-04-03 · 1 site observation

Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast CancerNCT00115505 · 2005-10-01 · 1 site observation

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung CancerNCT00450281 · 2005-10-01 · 1 site observation

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast CancerNCT00074152 · 2002-07-01 · 1 site observation

Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast CancerNCT00041119 · 2002-05-01 · 1 site observation

Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung CancerNCT00008385 · 2000-12-18 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.